GALACTUS Trial to assess GLP-1 and SGLT-2 agents for post-myocardial infarction inflammation
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)
Abstract
The GALACTUS Trial aims to evaluate GLP-1 receptor agonists and SGLT-2 inhibitors for reducing inflammation and improving outcomes after acute myocardial infarction.